Specify a stock or a cryptocurrency in the search bar to get a summary
Novartis AG ADR
NVSNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Address: Lichtstrasse 35, Basel, Switzerland, 4056
Analytics
WallStreet Target Price
115.66 USDP/E ratio
24.0511Dividend Yield
3.21 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures NVS
Dividend Analytics NVS
Dividend growth over 5 years
30 %Continuous growth
2 yearsPayout Ratio 5 years average
80 %Dividend History NVS
Stock Valuation NVS
Financials NVS
Results | 2019 | Dynamics |